Table 2. Association between TOX3 rs3803662 polymorphism and gastric cancer patients' survival.
| Genetic models | Genotypes | All cases | ||||
| Patients, n = 880 | Deaths, n = 408 | MST (months) | Log-rank p | HR (95% CI)1 | ||
| Codominant model | CC | 96 | 50 | 49.0 | 0.194 | 1 |
| CT | 522 | 230 | 80.0 | 0.77(0.57–1.05) | ||
| TT | 262 | 128 | 60.0 | 0.89(0.64–1.23) | ||
| Dominant model | CC | 96 | 50 | 49.0 | 0.200 | 1 |
| CT/TT | 784 | 358 | 74.0 | 0.81(0.60–1.09) | ||
| Recessive model | CC/CT | 618 | 280 | 74.0 | 0.332 | 1 |
| TT | 262 | 128 | 60.0 | 1.10(0.89–1.36) | ||
| Intestinal-type cases | ||||||
| Genetic models | Genotypes | Patients, n = 371 | Deaths, n = 143 | MST (months) | Log-rank p | HR (95% CI) |
| Codominant model | CC | 42 | 16 | 77.72 | 0.308 | 1 |
| CT | 217 | 78 | 78.52 | 0.95(0.55–1.64) | ||
| TT | 112 | 49 | 78.0 | 1.28(0.73–2.27) | ||
| Dominant model | CC | 42 | 16 | 77.72 | 0.720 | 1 |
| CT/TT | 329 | 127 | 75.62 | 1.06(0.63–1.79) | ||
| Recessive model | CC/CT | 259 | 94 | 79.42 | 0.125 | 1 |
| TT | 112 | 49 | 78.0 | 1.34(0.94–1.89) | ||
| Diffuse-type cases | ||||||
| Genetic models | Genotypes | Patients, n = 505 | Deaths, n = 262 | MST (months) | Log-rank p | HR (95% CI) |
| Codominant model | CC | 53 | 33 | 26.0 | 0.078 | 1 |
| CT | 303 | 150 | 56.0 | 0.65(0.44–0.95) | ||
| TT | 149 | 79 | 48.0 | 0.70(0.47–1.06) | ||
| Dominant model | CC | 53 | 33 | 26.0 | 0.030 | 1 |
| CT/TT | 452 | 229 | 56.0 | 0.67(0.46–0.96) | ||
| Recessive model | CC/CT | 356 | 183 | 50.0 | 0.869 | 1 |
| TT | 149 | 79 | 48.0 | 1.02(0.78–1.33) |
1
Adjusted for age, sex. 2Mean survival time was provided when MST could not be calculated. CI, confidence interval; HR, hazard ratio.